Brava Diagnostics Awarded Advanced Industry Grant from the State of Colorado
Grant supports development of a NextGen test for heart attack for emergency departments.
BOULDER, Colo., Nov. 25, 2019 /PRNewswire-PRWeb/ -- Brava Diagnostics, Inc., a company transforming acute care diagnostics with a next generation point-of-care platform, announced today that the Company was awarded $250,000 by the State of Colorado through Advanced Industry Early Stage Capital and Retention Grant Program. The Colorado Office of Economic Development and International Trade (OEDIT) awarded 24 Colorado start-ups funding. A total of $5,214,528 Proof-of-Concept and Early Stage Capital and Retention Grants that fuel the growth of Colorado's advanced industries were awarded in this reporting cycle.
"Funding such a diverse cross-section of innovative Colorado companies continues to advance Colorado's key industries and solidify our state's reputation as an innovation incubator," said Senior Manager of Advanced Industries, Katie Woslager. "Innovation drives economic growth and these grants directly support Colorado's vital innovation ecosystem."
Brava is developing a next generation test for heart attack: a point-of-care, high-sensitivity troponin test to assess patients with chest pain in 15 minutes. Rapid triage is critical to saving lives and improving quality of care in the emergency department. Of 8 million visits for chest pain in the U.S., 87% of patients do not receive a diagnosis of heart attack. High-sensitivity troponin tests can measure the protein 4-5 hours sooner than contemporary assays and have demonstrated more efficient rule-in and rule-out of heart attack. Rapid rule-out and safe discharge of low-risk patients eases crowding in the emergency department, reduces hospital admissions and improves patient satisfaction. Savings to the healthcare system are estimated at over $7 billion annually.
Byron Hewett, Co-Founder and CEO commented, "We are thrilled to have won this competitive Advanced Industry grant to support our product development program. U.S. and European guidelines are driving the shift to high-sensitivity troponin to improve diagnosis and rule-out of heart attack. Brava could be among the first high-sensitivity troponin point-of-care tests."
About Brava Diagnostics
Brava is developing a NextGen test for heart attack for the emergency department. Our first product is a point-of-care high-sensitivity troponin test to assess patients with chest pain to guide treatment decisions or safe discharge. Unlike the central lab that takes 60-90 minutes to return results, the Brava test delivers lab-quality results in 15 minutes, which means faster rule-in of heart attack and faster rule-out and safe discharge of low-risk patients. Rapid rule-out eases crowding in the ED, reduces the number of admissions, improves resource utilization, improves patient satisfaction and reduces costs to the healthcare system. Learn more at http://www.bravadx.com
About Advanced Industry Grants
The purpose of the Advanced Industry Early Stage Capital and Retention Grant Program is to fund early stage start-ups that have created viable products, meet a market need, and can be created or manufactured in Colorado and exported globally. The Advanced Industries include aerospace, advanced manufacturing, bioscience, electronics, energy, infrastructure engineering, and technology and information. See the OEDIT press release at https://choosecolorado.com/5-2-million-advanced-industries-awards-in-fall-2019-will-fuel-24-colorado-start-ups/
SOURCE Brava Diagnostics
Share this article